[Alpha-2 Macroglobulin Serum Level in Patients with Alpha-1 Antitrypsin Deficiency]

Area of Science:

• Biochemistry
• Genetics
• Proteomics

Background:

• Alpha-2 Macroglobulin (A2M) is a key plasma protein involved in protease regulation.
• Alpha-1 Antitrypsin Deficiency (AATD) disrupts protease-antiprotease homeostasis.
• Understanding A2M levels in AATD is crucial for comprehending disease pathophysiology.

Purpose of the Study:

• To compare Alpha-2 Macroglobulin (A2M) and Alpha-1 Antitrypsin (AAT) levels in AATD patients and healthy controls.
• To investigate the hypothesis that A2M levels are elevated in individuals with AATD.
• To explore potential correlations between AATD genotypes and A2M serum concentrations.

Main Methods:

• Nephelometry was used to quantify A2M and AAT serum levels.
• Polymerase Chain Reaction (PCR) identified Pi*Z and Pi*S polymorphisms.
• DNA sequencing was employed to detect rare genetic variants associated with AATD.

Main Results:

• A significant increase in serum A2M levels was observed in patients with the Pi*ZZ AATD genotype and AAT levels below 50 mg/dL.
• A statistically significant elevation in A2M was noted in the Pi*ZZ group compared to healthy volunteers.
• An inverse correlation between serum AAT and A2M levels was identified in individuals with the Pi*ZZ genotype.

Conclusions:

• Severe AATD, particularly the Pi*ZZ genotype with low AAT levels, is associated with elevated serum A2M.
• The findings suggest a compensatory mechanism or altered protease-antiprotease balance in severe AATD.
• Further research is warranted to clarify the clinical implications of increased A2M in severe AATD patients.